Navigation Links
Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
Date:3/4/2013

Toronto, Canada (PRWEB) March 04, 2013

With the advent of direct acting antiviral agents for the Hepatitis C virus (HCV), there has been a concerted effort to offer broad testing services and capabilities to assist clients at every stage of drug development. From lead compound optimization and resistance profiling to Phase IV marketing studies, LabCorp and its specialty testing laboratories offer specialized, proprietary testing. In fact, LabCorp offers global central laboratory testing services to support HCV trials around the world.

In this webinar, a thorough overview of currently available HCV capabilities will be presented, including:

  •     Technical overview of HCV assay services, including resistance testing (mutation detection and replicon-based DAA susceptibility assays), viral load assays, genotype/subtype characterization and IL28B allele testing
  •     Appropriate timing and circumstances for each specific test
  •     How these assays can be used to support regulatory filings
  •     How LabCorp’s global reach can help clients conduct more cost-effective clinical trials

The presentation will also highlight ongoing and future HCV assay development activities, such as the implementation of next generation sequencing platforms and the expanded presence in China, Southeast Asia and Europe.

For more information about this event or to register, visit: http://xtks.in/xto575-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10472827.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CNIO researchers take part in the most comprehensive personalized medicine study performed to date
2. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
3. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
4. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
5. CIVCO to Present Comprehensive Motion Management Solutions at ASTRO 2012 Booth #10003
6. Dr. Ross Kaplan Offers New Comprehensive Acne Package Treatment for Acne and Acne Scarring
7. Taylor-Wharton CryoScience 'Partners For Life' Awards Liquid Nitrogen Freezer to Comprehensive Cancer Center at University of Alabama at Birmingham
8. Rigaku introduces the world’s most comprehensive biological SAXS system for the home lab
9. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
Breaking Biology Technology:
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):